STANDARD DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

OLIPUDASE ALFA-RPCP (INTERIM)

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
OLIPUDASE ALFA-RPCP	XENPOZYME	48267		GPI-10 (3090156030)	

GUIDELINES FOR USE

1. Does the patient have a diagnosis of acid sphingomyelinase deficiency (ASMD) and meet **ALL** of the following criteria?
   - The patient has non-central nervous system manifestations of ASMD
   - The patient has baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels within 1 month of Xenpozyme initiation date

   If yes, **approve for lifetime by HICL or GPI-10 for 2 fills per 28 days.**
   If no, do not approve.

   DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

   Our guideline named **OLIPUDASE ALFA-RPCP (Xenpozyme)** requires the following rule(s) be met for approval:
   A. You have acid sphingomyelinase deficiency (ASMD: a type of rare genetic disorder that affects the body's ability to break down fat)
   B. You have non-central nervous system manifestations (affected organs are not in the brain or spinal cord) of ASMD
   C. You have baseline alanine aminotransferase (ALT: a type of liver enzyme test) and aspartate aminotransferase (AST: a type of liver enzyme test) levels within 1 month of Xenpozyme start date

   Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE
For further information, please refer to the Prescribing Information and/or Drug Monograph for Xenpozyme.

REFERENCES

- Xenpozyme [Prescribing Information]. Cambridge, MA: Genzyme, Corp., August 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 09/22
Commercial Effective: 09/16/22 Client Approval: [*PASS team fills this out*] P&T Approval: 10/22